WUXAY News and Press, Wuxi AppTec Co. Ltd. ADR From 03/31/24

2024-03-31 04:50:00 ET Summary South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770M. AnHeart Therapeutics, a New York-Hangzhou biopharma, will become part of Nuvation Bio (NYSE: NUVB) of New Yo...

2024-03-30 00:10:00 ET Summary I wrote recently about the politically fraught state of the relations of biopharma companies with Chinese outsourcing companies, of which WuXi is probably the most prominent. There are bills in the works in both the House (the BIOSECURE Act) and the ...

2024-03-24 07:15:00 ET Summary Shanghai WuXi Biologics (HK: 2269) has broken ground on a $1.4 billion facility in Singapore, the first CRDMO to offer end-to-end biologics research, development and manufacturing in the city-state. Novo Nordisk announced plans to invest $556 million...

WuXi AppTec Revenue Surpassed RMB40 Billion in 2023, and Adjusted Non-IFRS Net Profit Exceeded RMB10 Billion for the First Time PR Newswire Revenue Up 2.5% Year-over-Year to RMB40,341 Million ; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributa...

2024-03-17 03:20:00 ET Summary BIO, the global lobbying organization for biotechnology firms, forced WuXi AppTec to leave the group due to pressure from the US Congress. Germany’s Boehringer Ingelheim acquired an option to license drug candidates that treat all symptoms of ...

2024-03-14 07:20:30 ET More on WuXi AppTec, WuXi AppTec, etc. Potential U.S. Targeting Casts Shadow Over WuXi AppTec Family WuXi Biologics: Recent Share Price Recovery Isn't Sustainable Historical earnings data for WuXi AppTec Dividend scorecard for WuXi AppT...

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer. ...

2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...

WuXi AppTec Triples Peptide Manufacturing Capacity and Launches the New Taixing API Manufacturing Site PR Newswire Expansion Boosts Solid-Phase Peptide Synthesis Total Reactor Volume to 32,000 Liters in Response to Surging Demand SHANGHAI , Jan. 8, 2024 /...

2024-01-07 04:45:00 ET Summary Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Suzhou MediLink Therapeutics out-licensed global rights for its pre-clinical c-Mesenchymal epithelial transition factor ADC to R...